% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dietlein:877865,
      author       = {Dietlein, Felix and Kobe, Carsten and Hohberg, Melanie and
                      Zlatopolskiy, Boris D. and Krapf, Philipp and Endepols,
                      Heike and Täger, Philipp and Hammes, Jochen and
                      Heidenreich, Axel and Persigehl, Thorsten and Neumaier,
                      Bernd and Drzezga, Alexander and Dietlein, Markus},
      title        = {{I}ntraindividual {C}omparison of 18 {F}-{PSMA}-1007 with
                      {R}enally {E}xcreted {PSMA} {L}igands for {PSMA} {PET}
                      {I}maging in {P}atients with {R}elapsed {P}rostate {C}ancer},
      journal      = {Journal of nuclear medicine},
      volume       = {61},
      number       = {5},
      issn         = {2159-662X},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {FZJ-2020-02483},
      pages        = {729 - 734},
      year         = {2020},
      abstract     = {18F-prostate-specific membrane antigen (PSMA)-1007 is
                      excreted mainly through the liver. We benchmarked the
                      performance of 18F-PSMA-1007 against 3 renally excreted PSMA
                      tracers. Methods: Among 668 patients, we selected 27 in whom
                      PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL
                      (2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic
                      acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted
                      as equivocal or negative or as oligometastatic disease
                      (PET-1). Within 3 wk, a second PET scan with 18F-PSMA-1007
                      was performed (PET-2). The confidence in the interpretation
                      of PSMA-positive locoregional findings was scored on a
                      5-point scale, first in routine diagnostics (reader 1) and
                      then by an independent second evaluation (reader 2).
                      Discordant PSMA-positive skeletal findings were examined by
                      contrast-enhanced MRI. Results: For both readers,
                      18F-PSMA-1007 facilitated the interpretability of 27
                      locoregional lesions. In PET-2, the clinical readout led to
                      a significantly lower number of equivocal locoregional
                      lesions (P = 0.024), and reader 2 reported a significantly
                      higher rate of suspected lesions that were falsely
                      interpreted as probably benign in PET-1 (P = 0.023).
                      Exclusively in PET-2, we observed a total of 15
                      PSMA-positive spots in the bone marrow of 6 patients
                      $(22\%).$ None of the 15 discordant spots had a morphologic
                      correlate on the corresponding CT scan or on the subsequent
                      MRI scan. Thus, 18F-PSMA-1007 exhibits a significantly
                      higher rate of unspecific medullary spots (P = 0.0006).
                      Conclusion: 18F-PSMA-1007 may increase confidence in
                      interpreting small locoregional lesions adjacent to the
                      urinary tract but may decrease the interpretability of
                      skeletal lesions.},
      cin          = {INM-5 / INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406 / I:(DE-Juel1)INM-2-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31628219},
      UT           = {WOS:000530836100024},
      doi          = {10.2967/jnumed.119.234898},
      url          = {https://juser.fz-juelich.de/record/877865},
}